ACTA1 and pulmonary fibrosis: Moreover, CsA and HIF-1α inhibitors (HIFi) can reduce the expression levels of α-SMA and fibronectin, inducing dedifferentiation in myofibroblast-like cells (MyoLCs) derived from pulmonary fibrosis patients [42].